Click to copy
Press release content from Business Wire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Physicians’ Education Resource® to Host 37th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®

May 9, 2019

CRANBURY, N.J.--(BUSINESS WIRE)--May 9, 2019--Physicians’ Education Resource® (PER®), a worldwide leading resource for continuing medical education, will present the 37thAnnual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®. The conference will take place Nov. 6-8 at the New York Marriott Marquis in New York City.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190509005686/en/

This year’s program will once again be co-chaired by Dr. Benjamin Levy, clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Center at Sibley Memorial Hospital and associate professor of oncology at John Hopkins University School of Medicine. He will be joined by Dr. Adam M. Brufsky, professor of medicine, associate chief for the division of hematology/oncology, and co-director of the Comprehensive Breast Cancer Center and associate director of clinical investigations at the University of Pittsburgh, and Dr. William Oh, chief of the division of hematology and medical oncology, professor of medicine and urology and the Ezra M. Greenspan, M.D., professor in clinical cancer therapeutics at Icahn School of Medicine at Mount Sinai and deputy director at the Tisch Cancer Institute.

“We look forward to hosting one of PER’s marquee oncology CME conference this fall,” said Phil Talamo, president of PER®. “As new and exciting breakthroughs and rapid changes continue to occur in the management of solid and hematologic malignancies, it is important that we continue to educate health care professionals in the treatment of cancer on the on the latest developments in cancer care, including chemotherapies, targeted therapies and immunotherapies.”

Each year, Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow ®  brings together more than 1,000 health care professionals for three days to network with the top minds in oncology. At this year’s meeting, internationally renowned faculty will provide attendees with expert insights on the latest developments in cancer therapeutics, offering an unparalleled opportunity to learn how innovative approaches fit into existing treatment paradigms to optimize care and outcomes for their patients with cancer.

For more information and to register, click here.

About Physicians’ Education Resource ® (PER ® )

Since 1995, PER ® has been dedicated to advancing cancer care through professional education and now furthers patient care and treatment strategies on a wide variety of chronic illnesses and diseases. In 2016, PER ® initiated continuing medical education (CME) programming in the cardiovascular and endocrinology areas. While continuing to expand into topics outside oncology, PER ® remains the leading provider of live, online and print CME activities related to oncology and hematology. The high-quality, evidence-based activities feature leading distinguished experts who focus on the application of practice-changing advances. PER ® is accredited by the Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing. PER ® is part of the Cranbury, New Jersey-based MJH Associates, Inc., family of businesses. Learn more at http://www.gotoper.com and http://www.mjhassoc.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190509005686/en/


Alexandra Ventura, 609-716-7777, ext. 121

aventura@mjhassoc.comJohn Patricolo, 609-325-4630




SOURCE: Physicians’ Education Resource

Copyright Business Wire 2019.

PUB: 05/09/2019 11:24 AM/DISC: 05/09/2019 11:25 AM


All contents © copyright 2019 The Associated Press. All rights reserved.